
Magle Chemoswed Q3 2023 - DSM business advancements

Redeye leaves a comment on the Q3 report published by Magle yesterday. Overall, the report was in line with our expectations. While net sales came in slightly below our expectations due to a slower quarter for the contract manufacturing business, we are encouraged by the continuously growing sales from the DSM segment. We reiterate our previous fair value range (SEK25 – SEK58) with a base case valuation of SEK40 as we continue to have a positive outlook on the case.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Magle Chemoswed Q3 2023 - DSM business advancements](#)